For patients with limited-stage small cell lung cancer, adjuvant therapy with durvalumab leads to significantly longer ...

Adding perioperative durvalumab (Imfinzi) to neoadjuvant chemotherapy significantly improved survival outcomes in ...

BARCELONA — Adding the immune checkpoint inhibitor durvalumab to standard treatment for muscle-invasive bladder cancer (MIBC) ...

The BR.31 trial found that adjuvant durvalumab did not improve disease-free survival in patients with non-small cell lung ...

The HIMALAYA study showed that the combination of tremelimumab and durvalumab significantly improved overall survival in ...

The lack of a disease-free survival benefit with adjuvant durvalumab in early-stage resected non-small cell lung cancer in ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may ...

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard ...

Phase 2 results from the NeoCOAST-2 study have demonstrated that the combination of durvalumab with Dato-DXd yielded the ...

A regulatory decision on the application is expected during the fourth quarter of 2024. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License ...